evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

974 questions · 987 findings · 137 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 182 · 18.4%GRADE not reported 90 · 9.1%Very low 165 · 16.7%Low 312 · 31.6%Moderate 163 · 16.5%High 75 · 7.6%

Magnesium sulphate vs placebo (outcomes

Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)

Magnesium sulphate leads to lower cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).

2 findings from 1 review

Magnesium sulphate vs placebo (outcomes

Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)

Magnesium sulphate showed no clear difference in major neurodevelopmental disability (up to 2 years' corrected age)** compared with placebo (outcomes (moderate certainty).

1 finding from 1 review

Magnesium sulphate vs placebo (outcomes

Intraventricular haemorrhage, Papile grade 3/4 · women at risk of preterm birth (< 34 weeks' gestation)

Magnesium sulphate probably leads to lower severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)** compared with placebo (outcomes (moderate certainty).

1 finding from 1 review

Magnesium sulphate vs placebo (outcomes

Bronchopulmonary dysplasia/chronic lung disease · women at risk of preterm birth (< 34 weeks' gestation)

Magnesium sulphate showed no clear difference in chronic lung disease/bronchopulmonary dysplasia (newborn/infant)** compared with placebo (outcomes (low certainty).

1 finding from 1 review

Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection

Reduction in frequency and severity of drooling · Adults with Parkinson's disease and sialorrhea (drooling)

Type A botulinum toxin significantly reduced DSFS scores versus placebo (SMD -0.80, 95% CI -1.25 to -0.36; ungraded subgroup).

3 findings from 1 review

Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection

Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling)

Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).

3 findings from 1 review

Intervention not reported

Caesarean section (all indications) Â · women with an abnormal CTG in labour

It is very uncertain whether the intervention changes caesarean section (all indications) Â (very low certainty).

1 finding from 1 review

Intervention not reported

Assisted vaginal birth (all indications) Â · women with an abnormal CTG in labour

It is very uncertain whether the intervention changes assisted vaginal birth (all indications) Â (very low certainty).

1 finding from 1 review

Intervention not reported

Spontaneous vaginal birth  · women with an abnormal CTG in labour

It is very uncertain whether the intervention changes spontaneous vaginal birth  (very low certainty).

1 finding from 1 review

Intervention not reported

Caesarean section (all indications) · women with an abnormal cardiotocograph (CTG) in labour

It is very uncertain whether the intervention changes caesarean section (all indications) (very low certainty).

1 finding from 1 review

Intervention not reported

Assisted vaginal birth (all indications) Â · women with an abnormal cardiotocograph (CTG) in labour

It is very uncertain whether the intervention changes assisted vaginal birth (all indications) Â (very low certainty).

1 finding from 1 review

Intervention not reported

Spontaneous vaginal birth  · women with an abnormal cardiotocograph (CTG) in labour

It is very uncertain whether the intervention changes spontaneous vaginal birth  (very low certainty).

1 finding from 1 review